Compare Agilent Technologies Inc (A) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Goldman Sachs Group Inc — how do they compare? Agilent Technologies Inc trades at $129.13 (market cap $37.04B), while Goldman Sachs Group Inc trades at $1,029.19 (market cap $307.69B). The key difference: Goldman Sachs Group Inc is far larger — about 8.3× Agilent Technologies Inc's market cap, and Goldman Sachs Group Inc pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| A | GS | |
|---|---|---|
Market Cap | $37.04B | $307.69B |
Sector | Health | Financials |
52-Week High | $157.20 | $1.11K |
52-Week Low | $110.24 | $696.57 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.73% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Goldman Sachs (GS) trades at $1,055.29, up 3.36% with a bullish technical outlook and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue grew to $58.28B in 2025, and net income margin improved to 29.89%. The company is positioned to benefit from a surge in IPO activity, including leading high-profile deals like Anthropic's upcoming offering.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Key risks include volatile cash flows and high leverage, but robust investment banking pipelines and CEO optimism about market 'greed mode' support growth. Analyst sentiment is mixed but leans positive, with 40% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
